Wall Street brokerages expect Nightstar Therapeutics PLC (NASDAQ:NITE) to announce earnings of ($0.35) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Nightstar Therapeutics’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.37). The business is scheduled to report its next quarterly earnings report on Tuesday, April 2nd.

According to Zacks, analysts expect that Nightstar Therapeutics will report full year earnings of ($1.47) per share for the current year, with EPS estimates ranging from ($1.77) to ($1.25). For the next financial year, analysts forecast that the company will post earnings of ($1.56) per share, with EPS estimates ranging from ($1.93) to ($1.41). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Nightstar Therapeutics.

Several equities analysts have issued reports on NITE shares. Zacks Investment Research upgraded shares of Nightstar Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Wednesday, January 9th. Cantor Fitzgerald restated a “buy” rating and issued a $42.00 price target on shares of Nightstar Therapeutics in a research report on Thursday, January 31st. Leerink Swann cut shares of Nightstar Therapeutics from an “outperform” rating to a “market perform” rating and set a $25.18 price target for the company. in a research report on Tuesday, March 5th. Wedbush cut shares of Nightstar Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Monday, March 4th. Finally, UBS Group cut shares of Nightstar Therapeutics from a “buy” rating to a “neutral” rating and upped their price target for the company from $21.00 to $25.50 in a research report on Tuesday, March 5th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Nightstar Therapeutics has a consensus rating of “Hold” and an average price target of $27.24.

Shares of NASDAQ NITE opened at $25.52 on Tuesday. Nightstar Therapeutics has a 52-week low of $9.59 and a 52-week high of $29.55. The company has a market capitalization of $717.11 million, a price-to-earnings ratio of -15.66 and a beta of 3.15.

In other news, CEO David A. Fellows sold 8,733 shares of the stock in a transaction on Monday, January 7th. The shares were sold at an average price of $12.98, for a total transaction of $113,354.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory Scott Robinson sold 14,764 shares of the stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $11.15, for a total transaction of $164,618.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,328 shares of company stock valued at $291,734.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE acquired a new stake in shares of Nightstar Therapeutics in the second quarter valued at approximately $132,000. Janney Montgomery Scott LLC acquired a new stake in shares of Nightstar Therapeutics in the third quarter valued at approximately $204,000. JPMorgan Chase & Co. acquired a new stake in shares of Nightstar Therapeutics in the third quarter valued at approximately $214,000. Monashee Investment Management LLC acquired a new stake in shares of Nightstar Therapeutics in the third quarter valued at approximately $1,430,000. Finally, Tekla Capital Management LLC acquired a new stake in shares of Nightstar Therapeutics in the third quarter valued at approximately $3,065,000. Institutional investors own 39.15% of the company’s stock.

About Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.

Featured Story: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.